Q-omics provides the consensus-scored GUCY1B2 profile across patient tissues and cancer cell-line models. GUCY1B2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GUCY1B2 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, GUCY1B2 RNA expression shows 11,844 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where GUCY1B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCY1B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCY1B2 survival associations across molecular data types. GUCY1B2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCY1B2 RNA expression–survival associations across cancer types. High GUCY1B2 expression shows unfavorable associations in KIRC, LIHC, UVM, KICH and BRCA, but favorable associations in GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for GUCY1B2 RNA expression.
This table summarizes GUCY1B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GUCY1B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCY1B2 shows lower tumor expression in KICH and higher tumor expression in LUAD, COAD, STAD, BLCA and HNSC. The LUAD box plot shows higher GUCY1B2 RNA expression in tumor versus normal tissue (log2 FC = +0.982, t-test p < 0.001).
This table shows molecular features associated with GUCY1B2 in patient tissues and cancer cell lines. In patient samples, GUCY1B2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCY1B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in NCI60_ALL.
